BeStock  
Stocks › Biotechnology › URGN

UroGen Pharma Ltd URGN

US equityMarket cap rank #2953Biotechnology
$27.65 −$4.08 (-12.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.65 0.00%
Open$31.15
Prev close$31.73
Day range$27.57 – $31.90
Volume2.40M
Market cap$1.36B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±8.2%last 16 reports
Closed higher10 of 1663% of the time
Best reaction+21.9%
Worst reaction-18.0%

Stock move on the day after each report

-18.0%2023/Q4+2.6%2024/Q1+3.1%2024/Q2+0.2%2024/Q3+1.0%2024/Q4+7.3%2025/Q1-7.1%2025/Q2+21.9%2025/Q3-12.4%2025/Q4+10.2%2026/Q1+16.3%2026/Q2-16.5%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q34 Nov 2026Pre Market±15.8%-16.45%Bigger than priced
2026/Q25 Aug 2026Pre Market±16.8%+16.31%Within range
2026/Q16 May 2026Pre Market±16.5%+10.16%Within range
2025/Q42 Mar 2026Pre Market±19.2%-12.35%Within range
2025/Q36 Nov 2025Pre Market±29.0%+21.91%Within range
2025/Q27 Aug 2025Pre Market±13.3%-7.10%Within range
2025/Q112 May 2025Pre Market±25.1%+7.32%Within range
2024/Q410 Mar 2025Pre Market±18.7%+1.02%Within range
2024/Q36 Nov 2024Pre Market±14.9%+0.25%Within range
2024/Q213 Aug 2024Pre Market±19.8%+3.10%Within range
2024/Q113 May 2024Pre Market±17.2%+2.59%Within range
2023/Q414 Mar 2024Pre Market±12.8%-17.97%Bigger than priced
2023/Q314 Nov 2023Pre Market±44.5%-0.68%Within range
2023/Q210 Aug 2023Pre Market±18.1%+2.46%Within range
2023/Q111 May 2023Pre Market±20.9%+8.00%Within range
2022/Q416 Mar 2023Pre Market±23.2%-3.12%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Zusduri$68.04M 76.5%
  • Jelmyto$20.96M 23.5%

Latest reported quarter: Q3, ended Sep 2026

Revenue$89.00M+223.9% YoY
Operating profit$8.33M+130.4% YoY
Net profit-$1.46M+95.6% YoY
Diluted EPS-$0.03+95.7% YoY
Free cash flow-$15.27M+63.9% YoY
Operating cash flow-$15.20M

Revenue, last 8 quarters

$24.6MDec '24$20.3MMar '25$24.2MJun '25$27.5MSep '25$37.8MDec '25$51.0MMar '26$72.5MJun '26$89.0MSep '26

Net profit, last 8 quarters

$-37.5MDec '24$-43.8MMar '25$-49.9MJun '25$-33.3MSep '25$-26.4MDec '25$-23.6MMar '26$-14.4MJun '26$-1.5MSep '26

Profitability & balance sheet

Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
Return on assets-28.8%
Current ratio3.40
Liabilities / assets146.1%
Cash & investments$90.55M
Total debt$194.12M
Net cash (debt)-$103.57M

Discussion

No comments yet — be the first to weigh in on URGN.

Sign in to join the discussion.

Scroll to Top